The Esophageal Diseases drugs in development market research report provides comprehensive information on the therapeutics under development for Esophageal Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Esophageal Diseases. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Esophageal Diseases and features dormant and discontinued products.
GlobalData tracks 90 drugs in development for Esophageal Diseases by 80 companies/universities/institutes. The top development phase for Esophageal Diseases is phase i with 31 drugs in that stage. The Esophageal Diseases pipeline has 89 drugs in development by companies and one by universities/ institutes. Some of the companies in the Esophageal Diseases pipeline products market are: Korea United Pharm, Addpharma and Delta 4.
The key targets in the Esophageal Diseases pipeline products market include Potassium Transporting ATPase Alpha Chain 1, Interleukin 4 Receptor Subunit Alpha, and Glucocorticoid Receptor.
The key mechanisms of action in the Esophageal Diseases pipeline product include Potassium Transporting ATPase Alpha Chain 1 Inhibitor with 15 drugs in Pre-Registration. The Esophageal Diseases pipeline products include 11 routes of administration with the top ROA being Oral and eight key molecule types in the Esophageal Diseases pipeline products market including Small Molecule, and Monoclonal Antibody.
Esophageal Diseases overview
Esophageal Diseases, which are characterized by weakened muscles and narrowing of the esophageal opening, often lead to difficulties in digestion and swallowing. The esophagus is the tube-shaped muscle that connects the throat to the stomach. Esophageal diseases occur when the esophagus muscle and opening become weak. The most common problem with the esophagus is GERD (gastroesophageal reflux disease). With GERD, a muscle at the end of your esophagus does not close properly. This allows stomach contents to leak back, or reflux, into the esophagus and irritate it. Over time, GERD can cause damage to the esophagus.
For a complete picture of Esophageal Diseases’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
